



EUROPEAN HEMATOLOGY ASSOCIATION

Mutations in RAS pathway genes correlate with Type of Failure to Azacitidine: at Randomization onto the INSPIRE Trial


Koichi Takahashi, MD¹, Anna Jonasova, MD, PhD², Selina M. Luger, MD, FRCPC³, Aref Al-Kali, MD⁴, David Valcárcel, MD⁵, Erica D. Warlick, MD⁶, Wieslaw W. Jedrzejczak, MD, PhD⁷, María Díez-Campelo, MD, PhD⁸, Patrick S. Zbyszewski, MBA⁹, Christopher Cavanaugh⁹, Richard C. Woodman, MD⁹ & Steven M. Fruchtman, MD⁹, Guillermo Garcia-Manero, MD¹

¹University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX; ²1st Medical Department - Hematology, General Hospital, Prague, Czech Republic; ³Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; ⁴Division of Hematology, Mayo Clinic, Rochester, MN; ⁵Planta Baixa, Hospital Universitari Vall d'Hebron, Barcelona, Spain; ⁶Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN; ⁷MTZ Clinical Research, Medical University of Warsaw, Warsaw, Poland; ⁸Hematology Department, Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, Salamanca, Spain; ⁹Onconova Therapeutics, Inc., Newtown, PA; ¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

INTRODUCTION

- More than 45 mutations have been identified in association with HR MDS and the number of mutations increases and changes following HMA failure and leukemic transformation (Haferlach Leukemia 2014, Lindsley NEJM 2017);
- In the majority of patients with MDS (80%) co-mutations are present and the prognostic contribution of each individual mutation remains elusive, especially after adjusting for clinical variables such as IPSS-R score. Only a few mutations are predictive of poor prognosis (e.g. TP53, SF3B1) (Haferlach Leukemia 2014);
- N-RAS and K-RAS mutations as well as regulators of the Ras pathway (e.g. PTPN11, NF1) are frequently observed (15-20%) in HR MDS, however their clinical impact is unclear, especially in de novo MDS (Haferlach Leukemia 2014);
- Rigosertib (RGS) is a non-ATP-competitive small molecule RAS mimetic that has the potential to block RAS-RAF-MEK-ERK and PI3K-AKT-mTOR signaling pathways (Athuluri-Divakar 2016). Rigosertib has the potential to also inhibit wildtype upregulation of RAS;
- We report here the genomic profile of 190 patients with HMA failure HR MDS at the time of study entry prior to receiving rigosertib in the INSPIRE study (NCT02562443) an ongoing phase 3 randomized global study evaluating IV rigosertib vs Physicians Choice (PC) in patients with HR MDS post HMA failure;

INSPIRE (04-30) STUDY



Primary Objective: To compare the overall survival (OS) of patients in the rigosertib group vs PC arm in all patients and a sub-group of patients with IPSS-R very high risk;

Exploratory Objective: Correlation of overall survival and clinical responses with mutational status;

KEY INCLUSION CRITERIA

- INSPIRE (NCT02562443) is a global randomized Ph3 trial in pts with HR-MDS after HMA failure with an overall target enrollment of 360 pts which has recently been achieved.
- Key inclusion criteria includes:
 - age < 82 years;
 - RAEB-1, RAEB-2 or RAEB-t and ≥ 1 cytopenia;
 - Higher Risk MDS per IPSS-R Intermediate risk (IR), high risk (HR) and very high risk (VHR);
 - Duration of prior HMA ≤ 9 cycles within 12 months and last dose of HMA ≤ 6 months before enrollment;
 - One of the following:
 - Progression (2006 IWG criteria) at any time after initiation of AZA or DEC treatment or
 - Failure to achieve complete or partial response or HI (according to 2006 IWG) after at least
 - Six 4-week cycles of AZA or either four 4-week or four 6-week cycles of DEC or
 - Relapse after initial complete or partial response or HI (according to 2006 IWG criteria) or
 - Progression (2006 IWG criteria) at any time after initiation of AZA or DEC treatment or
 - Intolerance to azacitidine or decitabine


METHODOLOGY

- Bone marrow samples were collected at study baseline and at Months 2, 4 and 6 and every 6 months thereafter as well as at the end of treatment for mutational analysis as an exploratory endpoint;
- In this abstract we report the genomic characterization of baseline samples; future analyses will report longitudinal assessment while on therapy as well as at the time of disease progression
- Genomic DNA was extracted from diagnostic bone marrow or peripheral blood samples and targeted capture deep sequencing of 295 genes was performed (median sequencing depth 500x) using Agilent's SureSelect custom panel;
- Modified Mutect and Pindel were used to identify high-confidence somatic mutations;

TABLE 1: PATIENT DEMOGRAPHICS (N=190)

		Number of patients (%)
Sex	Female	67 (35)
	Male	121 (64)
	Unknown	2 (1)
Race	Asian	22 (12)
	Black	3 (2)
	White	152 (80)
	Other	6 (3)
	Unknown	7 (4)
Age (yr)	Median	73
	Range	54 – 82
ECOG performance Status	0	40 (21)
	1	87 (46)
	2	19 (10)
	Unknown	44 (23)
	MDS type	Primary (de novo)
WHO/FAB classification	Secondary	12 (6)
	Unknown	33 (17)
	RAEB-1	50 (26)
	RAEB-2	78 (41)
	RAEB-t	26 (14)
Failure type after the last HMA therapy	Unknown	36 (19)
	Progression	61 (32)
	Failure	59 (31)
	Relapse	29 (15)
	Intolerance	8 (4)
Revised IPSS score	Unknown	33 (17)
	Low	0
	Intermediate	19 (10)
	High	44 (23)
	Very High	93 (49)
	Unknown	34 (18)

FIGURE 1: GENOMIC PROFILING IN PATIENTS WITH HMA FAILURE AT BASELINE FOR INSPIRE STUDY



GENOMIC PROFILING IN PATIENTS WITH HMA FAILURE AT BASELINE ASSESSMENT FOR INSPIRE STUDY

- Data is presented as blinded aggregate results for both arms of the study;
- Baseline mutations are presented for 190 pts of which 157 pts were randomized and 33 pts were screen failures;
- Median age is 73 years (54-82). IPSS-R scores for the pts randomized were: Intermediate 19 (10%), High 44 (23%) and VHR 93 (49%);
- In total 55 different mutations were identified at baseline prior to pts receiving study treatment with either IV rigosertib or PC and the median number of mutations per pt was 3;
- The most common mutations identified in pts were *ASXL1* 37%, *TP53* 26%, *RUNX1* 26%, *TET2* 23%, *STAG2* 21%, *DNMT3A* 17%, and *SRSF2* 17%;

FIGURE 3: CORRELATION OF MUTATION AND BASELINE CLINICAL FEATURES




FIGURE 2: PAIR-WISE ANALYSIS OF MUTATION CO-OCCURRENCE





FIGURE 4: CORRELATION WITH MUTATIONS AND TYPES OF FAILURE



CONCLUSION(S)

- The baseline mutational analyses from the INSPIRE study provides important new insights regarding the genomic profile of patients with HMA failure, especially for the subset categorized as VHR;
- The genomic profile is representative of a cohort enriched for the VHR subset;
- RAS pathway mutations were observed more commonly in patients that progressed on HMA therapy vs patients that failed HMA therapy as defined by IWG 2006 criteria;
- Future genomic analyses of the INSPIRE study will expand the data set and will evaluate correlation of clinical responses with changes in mutational status;
- It is anticipated that these analyses will provide important new insights in the selection of mutations, including but not exclusively the RAS pathway, on the development of leukemic progression in patients with HR MDS following HMA failure and treatment rigosertib.

ACKNOWLEDGEMENTS

- Dr. Garcia-Manero, Guillermo; University of Texas MD Anderson Cancer Center
- Dr. Silverman, Lewis; Icahn School of Medicine at Mount Sinai
- Dr. Bajor, Rafael; The Regents of the University of California
- Dr. O'Connell, Casey; USC Norris Comprehensive Cancer Center
- Dr. Baer, Maria; University of Maryland Greenebaum Cancer Center
- Dr. Stiff, Patrick; Loyola University Medical Center
- Dr. Scott, Bart; Fred Hutchinson Cancer Research Center
- Dr. Warlick, Erica; University of Minnesota Physicians BMT Clinic
- Dr. Sayas, Hamid; Indiana University Melvin and Bren Simon Cancer Center
- Dr. Luger, Selina; University of Pennsylvania
- Dr. Arana-Yi, Cecilia; New Mexico Cancer Care Alliance
- Dr. Schaaf, Dale; Rutgers Cancer Institute of New Jersey
- Dr. Gamaleski, Steven; Henry Ford Health System
- Dr. Fanning, Suzanne; GHS Cancer Institute
- Dr. Moezi, Mehdi; Cancer Specialists of North Florida - Jacksonville
- Dr. Safah, Hana; Tulane University Hematology & Medical Oncology
- Dr. Keng, Michael; University of Virginia Cancer Center
- Dr. Yacoub, Abdurrahem; University of Kansas Cancer Center
- Dr. Al-Kali, Aref; Mayo Clinic
- Dr. Hansen, Vincent; Northern Utah Associates LLC
- Dr. Hansen, Vincent; Northern Utah Associates LLC
- Dr. Patel, Pragti; UT Southwestern Medical Center
- Dr. Mattison, Ryan; University of Wisconsin Clinical Science Center
- Dr. Anz, Bertrand; SCRI - Tennessee Oncology - Chattanooga
- Dr. Fenauz, Pierre; Saint-Louis Hospital, Department of Hematology Seniors
- Dr. Wattel, Eric; Centre Hospitalier Lyon Sud
- Dr. Thepot, Sylvain; Centre Hospitalier Universitaire, Angers
- Dr. Quesnel, Bruno; Claude Huriez Hospital, Department of Hematology
- Dr. Legros, Laurence; Archet 1 Hospital, Department of Clinical Hematology
- Dr. Clouseau, Thomas; Archet 1 Hospital, Department of Clinical Hematology
- Dr. Natarajan-Ame, Shanti; Hôpital Civil
- Dr. Mandac Roguj, Inga; Clinical Hospital Merkur, Clinic of Internal Medicine, Department of Hematology
- Czech Republic: Dr. Jonasova, Anna; General University Hospital in Prague, 1st Internal Clinic - Clinic of Hematology
- Czech Republic: Dr. Belohlavkova, Petra; University Hospital Hradec Králové, 4th Internal Clinic of Hematology
- Czech Republic: Dr. Hajek, Roman; University Hospital Ostrava, Department of Hematooncology
- Czech Republic: Dr. Machova, Renata; University Hospital Olomouc
- Germany: Dr. Giagounidis, Aristoteles; Marien Hospital Duesseldorf GmbH
- Germany: Dr. Platzbecker, Uwe; University Hospital Carl Gustav Carus
- Germany: Dr. Sockel, Katja; University Hospital Carl Gustav Carus
- Italy: Dr. Lughli, Monia; University Hospital "Maggiore della Carità" of Novara, Department of Oncology, Operating Unit of Hematology
- Italy: Dr. Cavo, Michele; Policlinic S. Orsola-Malpighi, Department of Hematology, Oncology and Laboratory Medicine, Operative Unit of Hematology - Cavo
- Italy: Dr. Ferrero, Dario; University Hospital San Giovanni Battista di Turin, Complex Structure of Hematology - U
- Italy: Dr. Liberati, Anna Marina; Hospital S. Maria di Terni, Department of Medicine and Medical Specialties, Complex
- Operative Structure of Oncohematology
- Italy: Dr. Rossi, Giuseppe; Civil Hospital of Brescia, Department of Clinical Oncology, Operative Unit of Hematology
- Italy: Dr. Voso, Maria Teresa; Policlinic Tor Vergata, Department of Medicine, Complex Operative Unit of Hematology
- Italy: Dr. Niscola, Pasquale; Hospital S. Eugenio
- Poland: Dr. Jedrzejczak, Wieslaw; MTZ Clinical Research Inc.
- Poland: Dr. Halla, Janusz; Oncology Center of Warmia and Mazury in Olsztyn, Teaching Department of Hematology
- Poland: Dr. Urbanowicz, Alina; Dr. Ludwik Rydygier Provincial Hospital in Suwalki, Department of Clinical Oncology and Hematology
- Russia: Dr. Gritsaev, Sergey; FSI Russian Scientific Research Institute of Hematology and Transfusiology
- Russia: Dr. Dudina, Galina; State Budget Healthcare Institution of Moscow "Moscow Clinical Scientific Center"
- Russia: Dr. Volodicheva, Elena; State Healthcare Institution of Tula Region "Tula Regional Clinical Hospital"
- Hungary: Dr. Rejtő, László; Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktató Kórház, Józsa András Oktatóközpont Hematológiai Osztály
- Estonia: Dr. Vilgimaa, Iige; North Estonia Medical Centre
- Switzerland: Dr. Bonadies, Nicolas; University Hospital of Hematology and Hematology Central Laboratory (UHN - H2L)
- Australia: Dr. Harrup, Rosemary Anne; Royal Hobart Hospital (RHH), Department of Hematology and Oncology
- Austria: Dr. Pleistoecker, Michael; Hansuch Hospital
- Poland: Dr. Wrobel, Tomasz; Independent Public Clinical Hospital #1 in Wrocław, Department of Hematology, Blood Tumors and Bone Marrow Transplantation
- UK: Dr. Killick, Sally; Royal Bournemouth Hospital, Department of Hematology
- Germany: Dr. Chromik, Joerg; Johann Wolfgang Goethe University Hospital, Center for Internal Medicine, Hematology
- Ireland: Dr. Enright, Helen; Adelaide and Meath Hospital Inc. National Children's Hospital, Department of Hematology
- Ireland: Dr. Cahill, Mary; Cork University Hospital
- Spain: Dr. Aman Sangerman, Montserrat; Institut Català d'Oncologia (ICO L'Hospitalet) - Hospital Duran i Reynals
- Spain: Dr. Font Lopez, Patricia; General University Hospital Gregorio Marañon
- Spain: Dr. Rosell, Ana-Isabel; Hospital Universitario Virgen de la Victoria Hospital de Día de Hematología, 1ª planta
- Spain: Dr. Díez Campelo, María; University Clinical Hospital of Salamanca, Department of Hematology
- Spain: Dr. Válcárcel Ferrerías, David; Hospital Universitario Vall d'Hebron Servei d'Hematologia i Hemoteràpia
- Spain: Dr. Xicoy Cirici, Blanca; ICO Badalona - Hospital Universitari Germans Trias i Pujol
- Japan: Dr. Utsuki, Kensuke; NTT Medical Center Tokyo
- Japan: Dr. Suzuki, Kenshi; Japanese Red Cross Medical Center
- Japan: Dr. Maito, Kazuyuki; Tokai Central Hospital
- Japan: Dr. Uoshima, Nobuhiko; Japanese Red Cross Kyoto Daini Hospital
- Japan: Dr. Makita, Masanori; National Hospital Organization Okayama Medical Center
- Japan: Dr. Nakamura, Shingo; Tokushima University Hospital
- Japan: Dr. Hidaka, Michihiro; National Hospital Organization Kumamoto Medical Center
- Japan: Dr. Yamauchi, Takahiro; University of Fukui Hospital
- Japan: Dr. Ishitsuka, Kenji; Kagoshima University Hospital
- Japan: Dr. Matsumura, Itaru; Kindai University Hospital
- Japan: Dr. Choi, Ilseung; National Hospital Organization Kyushu Cancer Center
- Japan: Dr. Fujita, Hiroyuki; Saiseikai Yokohamashi Nanbu Hospital
- Canada: Dr. Buckstein, Rena; Sunnybrook Research Institute, Odette Cancer Centre
- Canada: Dr. Assouline, Sarit; Jewish General Hospital
- Belgium: Dr. Beckers, Mariele; University Hospital Leuven, Campus Gasthuisberg
- Belgium: Dr. Graux, Carlos; Hôpital Universitaire Mont-Godinne
- Belgium: Dr. Mazure, Dominique; University Hospital Ghent
- Belgium: Dr. Sellieslag, Dominik; General Hospital Saint-Jam
- Sweden: Dr. Brolden, Per Anders; Karolinska University Hospital, Department of Hematology
- Russia: Dr. Doronin, Vadim; State Institution of Healthcare of Moscow City Clinical Hospital # 40 of Moscow Healthcare department
- Russia: Dr. Kosnova, Marina; State Autonomous Healthcare Institution of Kemerovo Region Kemerovo Regional Clinical Hospital named after S.V. Belyayev
- Russia: Dr. Gritsaev, Sergey; FSI Russian Scientific Research Institute of Hematology and Transfusiology

REFERENCES

- Athuluri-Divakar SK, Vasquez-Del Carpio R Dutta K, et al. A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling. Cell 2011;65:643-55
- Haferlach T, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014;28(2): 241-247.
- Onconova Therapeutics, Inc. (2018). Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE). Clinical Trials.gov Identifier: NCT02562443. Retrieved from: <https://clinicaltrials.gov/ct2/show/NCT02562443>.
- Lindsley et al. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. NEJM 2017; 376:536-547. DOI: 10.1056/NEJMoa1611604
- Mufti, G. J., Best, S., Lea, N., Silverman, L. R., et al. (2014). Mutational Profile and Karyotypic Abnormalities of a Cohort of Clinical Trial Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Following Failure of Hypomethylating Agents (HMAs): Impact on Response to Rigosertib Therapy. Blood, 124(21),3258.

CONTACT INFORMATION

Richard C. Woodman, MD
Onconova Therapeutics, Inc., Newtown, PA
rwoodman@onconova.us

Koichi Takahashi, MD
University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX
KTakahashi@mdanderson.org